Plasmid DNA is the building block of advanced therapies. As these therapies take off, so does manufacturing demand. By switching to modern chromatography resins, Cobra Biologics was able to increase binding capacity and flow rates up to 50% to address the increasing demands for high quality plasmid DNA.
February 13, 2020